TABLE 1.
MICs of HTS hit, compound A, and amoxicillin against several bacterial and eukaryotic speciesa
| Organism (n) | Description | MIC (μg/ml) of: |
||
|---|---|---|---|---|
| HTS hit | Compound A | Amoxicillin | ||
| Helicobacter pylori (4) | Clinical isolates | 0.5 to 2 | 0.13 to 0.5 | 0.008 to 0.25 |
| H. pylori SS1 | Strain used in efficacy studies | 0.5 | 0.25 | 0.25 |
| H. pylori ARHp80 | Clinical isolate | 2 | 0.25 | 0.008 |
| H. pylori ARHp80.2 (MurI+) | Isogenic MurI-overexpressing strain of ARHp80 (12) | 16 | 64 | 0.008 |
| H. pylori ARHp80 HefC− | Isogenic efflux compromised strain of ARHp80 (17) | 0.5 | 0.13 | 0.0009 |
| Streptococcus pneumoniae (4) | Clinical isolates, including PRSP | >64 | >64 | 0.016 to 8 |
| Staphylococcus aureus (2) | Clinical isolates, including MRSA | >64 | >64 | 0.25 to 64 |
| Haemophilus influenzae (3) | Clinical isolates, including β-lactamase positive | >64 | >64 | 0.125 to >64 |
| Escherichia coli | Clinical isolate | ≥64 | >64 | >64 |
| Moraxella catarrhalis | Clinical isolate | 8 | >64 | NDb |
| Fusobacterium necrophorum | Clinical isolate | ND | >64 | ND |
| Bacteroides thetaiotaomicron | Clinical isolate | ND | >64 | ND |
| Bacteroides fragilis | Clinical isolate | ND | >64 | ND |
| Clostridium difficile | Clinical isolate | ND | 32 | ND |
| Fusobacterium mortiferum | Clinical isolate | ND | >64 | ND |
| Candida albicans | Yeast | >64 | >64 | >64 |
| A549 | Human cell line | ND | >64 | >64 |
a
PRSP, penicillin-resistant S. pneumoniae; MRSA, methicillin-resistant S. aureus.
b
ND, not determined.